Results 201 to 210 of about 288,402 (222)

Aggressive Head and Neck Squamous Cell Carcinoma in the Setting of GATA2 Deficiency

Head &Neck, EarlyView.
ABSTRACT Background GATA2 deficiency is a rare genetic disorder associated with hematologic, infectious, and neoplastic complications. We report a case of a patient with GATA2 deficiency who developed aggressive squamous cell carcinoma (SCC) of the head and neck, an atypical manifestation of this condition.
Brejjette Aljabi, James A. Stewart, Kirk Withrow, Carissa M. Thomas   +3 more
wiley   +1 more source

Neoadjuvant immunotherapy for NSCLC: superior combination strategies, optimal treatment cycles, and predictive indicators from a Bayesian meta-analysis. [PDF]

Front Immunol
Liu Y, Long J, Deng H, Chen W.
europepmc   +1 more source

Differences in PD‐L1, PD‐L2, and EGFR Expression Between Naive and Recurrent Tumors in Patients With Head and Neck Squamous Cell Carcinoma: A Retrospective Study

Head &Neck, EarlyView.
ABSTRACT Background The efficacy of anti‐PD‐1 and EGFR therapies for head and neck squamous cell carcinoma (HNSCC) can be predicted using various markers; however, the stability of these markers remains unclear. Methods In this retrospective study, laboratory findings and tissue expression of PD‐L1, PD‐L2, and EGFR were analyzed in 79 paired naive and ...
Ryosuke Sato, Takahiro Inoue, Risa Wakisaka, Hiroki Komatsuda, Michihisa Kono, Hidekiyo Yamaki, Kenzo Ohara, Takumi Kumai, Akemi Kosaka, Takayuki Ohkuri, Toshihiro Nagato, Kan Kishibe, Hiroya Kobayashi, Miki Takahara   +13 more
wiley   +1 more source

A rapid state-of the-art review of client-reported outcomes measures used to assess dogs' clinical signs and quality of life during chemotherapy. [PDF]

BMC Vet Res
Harris J, Fournier Q, Sutton K, Armes J, Ream E, Bacon N.   +5 more
europepmc   +1 more source

Comparative effectiveness and safety of treatment regimens for recurrent advanced ovarian cancer: a systematic review and network meta-analysis. [PDF]

World J Surg Oncol
Huo X, Tian T, Zhang X, Zhou N.
europepmc   +1 more source

Therapeutic targeting of chromatin alterations in leukemia and solid tumors

International Journal of Cancer, EarlyView.
Abstract Alterations in chromatin conformation and post‐translational modification of histones have become increasingly recognized as critical drivers of cancer development, progression, and therapy resistance. Recent advances in drug development have led to the establishment of several highly selective small molecule inhibitors, several of which are ...
Florian Perner, Tobias Berg, Daniel Sasca, Sophie‐Luise Mersiowsky, Jayant Y. Gadrey, Johanna Thomas, Michael W. M. Kühn, Michael Lübbert   +7 more
wiley   +1 more source

Chemotherapy combined with immunotherapy in patients with gastric cancer: protocol for a systematic review. [PDF]

BMJ Open
Han Y, Yang W, Meng Y, Cai Z, Zhang B.
europepmc   +1 more source

Real‐world treatment patterns and outcomes based on RAS/BRAF status in metastatic colorectal cancer—Analysis of the Prospective Dutch Colorectal Cancer cohort

International Journal of Cancer, EarlyView.
What's New? The treatment landscape of metastatic colorectal cancer has evolved into a continuum of care with guideline recommendations depending on molecular status. However, guidelines are primarily based on the results of randomized clinical trials, which do not fully align with clinical practice.
Sietske C. M. W. van Nassau, Koen Zwart, Frederieke H. van der Baan, Geraldine R. Vink, Marloes A. G. Elferink, Petur Snaebjornsson, Anne M. May, Miriam Koopman, Jeanine M. L. Roodhart   +8 more
wiley   +1 more source

Cost-effectiveness analysis of toripalimab combined with nab-paclitaxel as a first-line treatment for advanced TNBC in the US. [PDF]

PLoS One
Chen P, Qiao D, Xiao L, Deng G, Yang Q, Tian R.   +5 more
europepmc   +1 more source

GEMPAX, do we have another second-line option after mFOLFIRINOX in pancreatic cancer? [PDF]

Ann Transl Med
Boyle K, Perez KJ.
europepmc   +1 more source